Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.

已完结 10 由何曼慈发布于 2026/6/17 10:01:53

DOI:10.1016/S2352-3026(24)00347-8
作者：Frida Bugge Askeland,?Einar Hauk?s,?Tobias S Sl?rdahl,?Anja Klostergaard,?Tatjana Alexandersen,?Anna Lysén,?Pegah Abdollahi,?Lene Kongsgaard Nielsen,?Emil Hermansen,?Fredrik Schjesvold
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1016/S2352-3026(24)00347-8

Elsevier

Abstract：Background: Adding anti-CD38 monoclonal antibodies to standard therapies can improve outcomes in patients with multiple myeloma. Long-term treatment with corticosteroids increases the risk o

应助信息

1天前

Book学术机器人

9fed7a6ab49611f09e5934735aa3bc31.pdf 已采纳

1天前

Book学术机器人

2026/6/17 10:01:53 Book学术AI机器人已找到文献并上传

2026/6/17 10:01:53 Book学术AI机器人收到请求，开始寻找文献

2026/6/17 10:01:53 已向机器人发送请求

1天前

何曼慈发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Elsevier Altering Substrate Specificity and Detecting Processivity in Nucleases